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Localized delivery of drugs is an emerging field both with regards to drug delivery during
disease as well as in tissue engineering. Despite significant achievements made in the last
decades, the efficient delivery of proteins and peptides remains challenging, especially in
cases requiring long-term release of proteins after application. The localized delivery of
nucleic acids (NA) represents an interesting alternative due to higher physicochemical
stability of NA, increased efficiency by harnessing cells as bioreactors for the production of
required proteins and improved versatility with regards to expression of specific proteins
through plasmid DNA or repression of gene products through siRNA. However, unlike most
proteins and peptides, NA must be delivered to the cytoplasm or nucleus to be efficacious,
resulting in significant delivery challenges. We herein describe frequently used non-viral
vectors for the delivery of NA including polyplexes, lipoplexes and lipopolyplexes and
summarize recent developments in the field of nucleic acid delivery systems for local
application based on hydrogels, solid scaffolds and physical delivery methods. The chal-
lenges associated with the different approaches are identified and options to address these
challenges are discussed.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The efficient delivery of nucleic acids (NA) is one of the most
exquisite challenges to formulation scientists nowadays.
Unlike small chemical drugs and most biologic drugs, NA
must be delivered into the cytoplasm or into the nucleus to be
effective. Small interfering RNA (siRNA) and antisense oligo-
nucleotides interact with mRNA and therefore must beTechnology, School of Lif
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University. Production an
ns.org/licenses/by-nc-ndtransported to the cytoplasm. However, transport of NA
across the cell membrane is challenging due to its negative
charge and high molecular weight [1]. Plasmid DNA (pDNA)
additionally requires translocation into the nucleuswhere it is
transcribed into mRNA, eventually resulting in protein
synthesis.
From a physicochemical and formulation point of view NA
are almost ideal drug molecules. They possess high stability
against both chemical and physical degradation, which ise Sciences, University of Applied Sciences and Arts Northwestern
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from fossils of extinct species and the remarkable half-life of
DNA of 521 years [2,3]. It is therefore not surprising that
several studies investigating the stability of formulated NA
yielded promising results, especially when nucleic acids were
protected from hydrolytic and enzymatic degradation, e.g.
through freeze-drying [4e6]. It is also important to note that
NA potentially require significantly less formulation devel-
opment work once an optimal formulation has been found
compared to other macromolecular drugs such as proteins
and peptides. The relatively simple structure of NA results in
minimal changes of physicochemical properties of NA when
changing the sequence. In contrast, exchange of a single
amino acid may result in significantly changed structure and
physicochemical properties in the case of proteins and pep-
tides [7,8]. Therefore, it is reasonable to assume that refor-
mulation efforts to fulfill the needs of NAwith a new sequence
will be minimal. Furthermore, NA, especially siRNA and
antisense oligonucleotides can be simply produced by chem-
ical synthesis with good yield and in high purity. In contrast,
production of proteins such as monoclonal antibodies or
growth factors requires a cellular expression system and
extensive purification and/or refolding [9]. Finally, NA possess
high specificity, resulting in expression of a specific protein
(plasmid DNA) or inhibition of a specific target gene (siRNA,
antisense oligonucleotides), potentially maximizing the ratio
of desired to undesired effects compared to alternative ther-
apies [10].
Apart from the numerous advantageous properties of NA,
the requirement for delivery into the cytoplasm or nucleus
represents a significant challenge. This challenge is addressed
using attenuated viral vectors as delivery systems or non-viral
delivery strategies. A discussion of the general advantages
and disadvantages of viral versus non-viral vectors is beyond
the scope of this review and the reader is referred to the re-
view by Guo et al. for detailed information on this topic [11].
We herein focus on non-viral delivery strategies, which are
often preferred because of safety concerns associate with viral
vectors and versatility and ease of modification of non-viral
vectors [11].
In most studies, systemic administration of NA delivery
systems through the parenteral route is investigated, pri-
marily because of its versatility, e.g. with regards to treatment
of distant or disseminated cells, mostly in the context of
tumor therapy. However, achieving efficient delivery of NA to
target cells after parenteral application requires overcoming
numerous extracellular and intracellular barriers. Stability
and compatibility of the carrier system in the blood stream
must be maintained to achieve prolonged circulation, allow-
ing the delivery system to reach its target site. This entails
surface modification with hydrophilic polymers to avoid up-
take of the delivery system by the reticulo-endothelial system
(RES), crosslinking to prevent premature release of the NA
cargo and control of delivery system size to avoid blocking of
capillaries and to allow extravasation at the target site, e.g. in
the tumor or liver [12,13]. Additionally, active or passive tar-
geting strategies may facilitate the efficient extravasation and
cellular uptake at the site of action. In recent years, stimuli-
responsive systems have been developed, further improving
accumulation of the delivery system at the site of action.These systems change their physicochemical properties in
response to extracellular stimuli such as changes of the pH
value, enzymatic environment etc. [14,15]. It is therefore
obvious that the successful development of NA delivery sys-
tems for systemic administration requires an optimal com-
bination of different properties within the delivery system,
representing a significant formulation challenge. Further-
more, the clinical application of these delivery systems has
been significantly limited because of concerns with regards to
toxicity of the vehicle and unsatisfactory delivery efficiency.
While themajority of studies has focused on improving the
efficiency, stability and compatibility of delivery systems for
systemic application, localized delivery of NA represents an
interesting but largely untapped alternative, worthy of
increased exploration. While it is certainly not possible to
achieve the versatility of systemic application, e.g. regarding
transfection of distant or disseminated cells, localized de-
livery avoids several major barriers associated with systemic
delivery and is therefore more likely to result in safe and
efficacious therapy. Achieving sufficiently high drug concen-
trations at the target site is a common challenge in drug
therapy. In the case of NA delivery this general challenge is
aggravated by the necessity of intracellular delivery of NA [9].
Because of the sensitivity of NA towards enzymatic degrada-
tion, encapsulation is often required but on the other hand
efficient release must be maintained [1]. These requirements
increase the complexity of delivery systems, especially in the
case of systemic delivery.
Within this review, we seek to give an overview of the
current status of localized delivery of NA using non-viral de-
livery systems. The discussion is however focused to topical
delivery in the broadest sense, excluding oral, nasal and pul-
monary delivery as these delivery routes have additional
special requirements to the delivery system. We shortly
portray non-viral vectors that are employed for localized de-
livery of NA and review recent systems for localized NA de-
livery based on various matrices. Our aim is to highlight
challenges but also opportunities associated with this
approach to NA delivery and discuss potential fields of
application.2. Non-viral nucleic acid delivery systems
employed for localized delivery
The high molecular weight and negative charge of NA repre-
sents a major hurdle to efficient cellular uptake. For most cell
types, the size requirement for particle uptake is in the rage of
up to 200 nm, significantly smaller than the hydrodynamic
diameter of DNA of a few thousand base pairs [16]. Further-
more, negatively charged moieties anchored to the cell
membrane result in electrostatic repulsion of negatively
charged NA. Non-viral delivery agents are designed to
improve cellular uptake efficiency either through complexa-
tion and charge reversal of NA or through physical methods
allowing NA to directly enter the cell. However, the challenge
with such delivery systems is on the one hand to prevent the
NA degradation within themicro- or nanoparticles and on the
other hand to achieve efficient intracellular release [1].
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Cationic polymers such as polyethylenimine (PEI), chitosan or
dendrimers are among the most studied non-viral vectors for
NA [17e20]. These polymers proved to be highly efficient
in vitro, and several are commercially available as trans-
fection agents (JetPEI, Polyplus transfection SA; ExGen500,
Biomol GmbH).
Positively charged polymeric nanocomplexes (polyplexes)
in the size range of tens to hundreds of nanometers are
spontaneously formed when NA and suitable cationic poly-
mers are mixed under appropriate conditions. Polyplexes
facilitate cell attachment through electrostatic interaction,
internalization by endocytosis and endosomal escape
[18,21,22]. One of the main advantages of polymeric systems
for non-viral delivery is their ease of modification, allowing
straightforward design and synthesis of multifunctional de-
livery systems [11]. Some of these modifications include the
shielding of surface charge through modification with hy-
drophilic polymers prior to [23] or after complex formation
[24] with NA. Furthermore, conjugation of targeting moieties
can be performed in a similar fashion either directly [25] or
via grafted hydrophilic polymers [26]. Biodegradable cross-
linking, e.g. using bioreducible linkers, is another potential
modification allowing tailoring the stability of polyplexes in
different environments to specific needs [27,28]. However,
cytotoxicity of polycations is one of the major problems,
which was frequently found to correlate with transfection
efficiency [29,30]. Several groups addressed this issue, e.g.
through bioreducible crosslinks in the polymer backbone,
resulting in improved degradation and potentially improved
excretion [31,32]. A detailed overview of the current status of
polymeric non-viral vectors can be found in [33] and advan-
tages and disadvantages of polymeric non-viral vectors are
discussed in [17].
2.2. Lipid-based systems (Lipoplex)
Lipoplexes are formed through the interaction of anionic NA
with the surface of cationic liposomes, resulting in aggregated
and multilamellar complexes. The challenges associated with
cationic liposomes as a vector for NA delivery are their high
zeta potential, low transfection efficiencies and often an
inefficient protection against lysosomal NA degradation [4].
Lipid-based systems were among the first non-viral vectors
used to transfer NA into cells. Felgner et al. showed in 1987
that N-[1-(2, 3-dioleyloxy)propyl]-N,N,N-trimethylammonium
chloride (DOTMA), a synthetic cationic lipid, is able to
condense plasmid DNA (pDNA) and to transfect different cell
lines in vitro [34]. The complexation efficiencywith pDNAwas
found to be close to 100% and it was observed that complexes
fuse with the cell membrane, resulting in efficient intracel-
lular delivery of the cargo [34,35]. The interaction with the
cell surface is thought to be primarily due to electrostatic
interaction of positively charged lipoplexes with negatively
charged residues at the cell surface, such as sialic acid.
In addition, hydrophobic interactions contribute to fusion
with the cell membrane and cargo delivery. In this regard,
the addition of neutral helper lipids like dio-
leoylphosphatidylethanolamine (DOPE) or cholesterol resultsin stabilization of liposomes and improved membrane fusion
and hence improves transfection efficiency [36]. Later studies
found that efficient transfection depends on clathrin-
mediated endocytosis and direct translocation of NA across
the cell membrane is of only minor importance [22,37]. How-
ever, similar to the polymeric systems, cytotoxicity is a major
concern. Toxicity was frequently found to be associated with
the charge ratio between NA and cationic lipid, the dose
administered and the type of reagent or cell type [38]. Oneway
to deal with these toxicity issues is the local administration of
lipoplexes, reducing the effects on non-target cells. Numerous
improvements and modifications to the basic concept of lip-
ofection as described above have been published, including
stabilized liposomes, immunoliposomes and stimuli-
responsive liposomes. The reader is referred to [39,40] for a
detailed discussion of current lipoplex systems and to refer-
ences [38,39] for an in depth discussion of advantages and
disadvantages of lipoplexes as vectors for NA.
2.3. Lipopolyplex
Lipopolyplexes, representing ternary complexes composed
of cationic polymers, cationic liposomes and NA, were
developed in an attempt to combine the advantageous
properties of polyplexes and lipoplexes. Besides improve-
ments with regards to stability in the presence of serum,
particle size and reproducibility of transfection, lip-
opolyplexes were shown to significantly increase trans-
fection efficiency compared to polyplexes [41,42]. Through
further supplementation with hyaluronic acid or heparin,
lipopolyplexes with very low immunostimulatory potential
compared to traditional lipopolyplexes were obtained [43].
Recently, structurally stabilized lipopolyplexes consisting of
lipoplexes which were alternatively coated with poly(acrylic
acid) and polyethylenimine were prepared [44]. These lip-
opolyplexes showed improved transfection efficiency and
reduced cytotoxicity compared to various polyplexes and
lipoplexes and commercial lipofectamine. Lipopolyplexes are
therefore an efficient alternative to traditional lipo- and
polyplexes with reduced cytotoxicity. Additional information
on the advantages and disadvantages of lipopolyplexes can
be found in [44].3. Delivery systems for localized release of
nucleic acids
3.1. Local delivery of naked nucleic acids
The direct administration of NA as a liquid is certainly the
simplest form of local delivery, it is highly attractive due to
simple formulation development and administration and,
under appropriate conditions, results in efficient NA delivery.
As an example, the treatment of choroidal neovascularization
by direct injection of stabilized siRNAs was investigated by
Shen et al. [45]. In this study, Sirna-027, a chemically stabilized
siRNA against vascular endothelial growth factor receptor 1
(VEGFR1), was administered locally through intravitreal or
periocular injections in a murine model of choroidal or retinal
neovascularization. Upon injection of Sirna-027, VEGFR1
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siRNA was detected in retinal cells for 4e5 days after intra-
vitreal injection, siRNA was also able to penetrate the sclera
and choroidea after periocular injection and was detectable in
the retina for at least 5 days. Finally, treatment with Sirna-027
resulted in efficient suppression of ocular neovascularization
inmurinemodels of choroidal and retinal neovascularization.
The safety and tolerability of direct intravitreal injection of
Sirna-027 was later tested in a phase 1 clinical study in 26
patients with choroidal neovascularization resulting from
neovascular age-related macular degeneration [46]. Intra-
vitreal injections of 100e1600 mg of Sirna-027 were well
tolerated and no dose-limiting toxicity was observed. Sec-
ondary objectives including retinal thickness and visual acu-
ity were found to be stabilized or improved after treatment,
respectively. Further phase 1 and phase 2 studies evaluating
stabilized siRNA targeting the RTP801 gene were performed in
patients with neovascular age-related macular degeneration
[47] and diabetic macular edema [48], respectively. Similar to
the study on Sirna-027, intravitreal injections of siRNA in
these two studies were generally well tolerated and safe. Only
few mild to moderate treatment-related adverse events were
observed. However, Kleinman et al. demonstrated that inhi-
bition of VEGF expression and reduction of neovascularization
might be due to unspecific activation of cell surface Toll-like
receptor 3 (TLR3) [49]. In addition, it was shown that cellular
uptake of siRNA was not required for this effect. These ob-
servations as well as failure to meet efficacy requirements in
clinical studies resulted in discontinuation of the develop-
ment of ocular injection of Sirna-027.
Meuli et al. reported that direct injection of naked plasmid
DNA into full-thickness wounds in amurinemodel resulted in
efficient local transfection of macrophages, fibroblasts and
adipocytes [50]. Interestingly, transfection efficiency of naked
DNA was comparable to efficiency of optimized cationic
liposome/DNA complexes. Similar results were obtained in
pig skin, in rats and another murine model before [51e53].
Local transfection efficiency after administration of naked
DNA in the skin can be further improved through oscillating
solid microneedles [54,55].
3.2. Composite systems
The development of drug delivery systems for the localized
release of NA, apart from application of naked NA described
above and physical methods described below, frequently re-
quires the combination of a component that condenses NA
and allows the transfection of target cells (vector) and amatrix
that controls release of the vector and provides physical
support. In the simplest case, NA or NA/vector combinations
are locally administered as a solution without the need for a
supportingmatrix. If amatrix is used, NAmay be incorporated
into the matrix (encapsulation) or may be attached to the
matrix surface (immobilization).
3.2.1. Hydrogels
Hydrogels are among themost frequently used systems in the
field of localized therapy, including tissue engineering. The
well hydrated, tissue-like environment of hydrogels, their
variability with regards to the chemical composition andmodification as well as the typically mild, aqueous fabrication
conditions all render hydrogels ideally suited as scaffolds for
localized NA delivery. Hydrogels are typically formed either by
crosslinking or by self-assembly from hydrophilic polymers of
natural, synthetic or semi-synthetic origin. The release of
encapsulated NA can be controlled via the pore size of the
hydrogel, its degradation rate or through physical interaction
or chemical conjugation of the vector system with hydrogel
components. In the following sections, we will highlight the
advantages and challenges associated with various hydrogel-
based delivery of non-viral vectors. For an in depth discussion
of properties and application of natural and semi-synthetic
polymers for drug delivery the reader is referred to [56].
3.2.1.1. Hydrogels based on natural polymers. Natural poly-
mers like collagen, fibrin or alginate were frequently used to
prepare NA releasing hydrogels. Natural hydrogels in this re-
gardmay serve as a reservoir for NA vectorswith release being
controlled by the hydrogel pore size, vectorematrix in-
teractions and/or degradation. Such systems have been
developed based on collagen [57e59], fibrin [60,61], alginate
[62,63], chitosan [64] and hyaluronic acid [61]. The sustained
release of NA from these biocompatible scaffolds frequently
resulted in improved transfection efficiency both in vitro and
in vivo [65,66]. Furthermore, sustained release of polyplexes or
lipoplexes was often found to significantly reduce the cyto-
toxicity of non-viral vectors [59,67]. Retention of the vector
within the hydrogel and hence release rate can bemodified by
variations of the vector and hydrogel chemistry. As an
example, Cohen-Sacks et al. modified a collagen hydrogel
matrix with poly-L-lysine to improve the retention of plasmid
DNA through non-specific electrostatic interactions [57].
Alternatively, NA or vector, i.e. polyplexes can be chemically
crosslinked with the hydrogel matrix. Capito et al. showed by
direct comparison of a) simple soaking of a pre-crosslinked
hydrogel and b) crosslinking of plasmid DNA with the scaf-
fold, that the latter method allows to reduce burst release and
to link DNA release to hydrogel degradation [58]. Similarly,
control over sustained release of siRNA/PEI complexes was
achieved by covalent attachment of PEI via ester linkages to
photocrosslinked dextran hydrogel [68]. However, aggregation
of non-viral vectors during incorporation into hydrogels
associated with loss of activity was identified as a major lim-
itation. Lei et al. recently developed a procedure termed caged
nanoparticle encapsulation allowing loading of concentrated
non-viral vector nanoparticles into various hydrogels avoid-
ing aggregation [61,69]. The encapsulation process consisted
of lyophilization of polyplexes using agarose and sucrose and
subsequent reconstitution of the lyophilized powder with
hydrogel precursor, followed by crosslinking for hydrogel
formation (Fig. 1).
3.2.1.2. Hydrogels based on synthetic polymers. While natural
hydrogels often excel with regards to biocompatibility,
biodegradability and can be obtained from renewable re-
sources [56], synthetic polymers allow simple chemical
modification and functionalization, improved control over
composition and properties and often carry lower risk of
immunogenicity than natural polymers [70]. It is therefore not
surprising that numerous hydrogel systems for the delivery of
Fig. 1 e (A) Schematic representation of caged nanoparticle encapsulation process: polyplexes consisting of plasmid DNA
and PEI were mixed in the presence of agarose and sucrose and lyophilized. The lyophilizate was reconstituted with
hydrogel precursor solution and subsequently crosslinked to prepare hydrogels. (B) Transfection efficiency of polyplexes
after lyophilization depending on sucrose concentration. Polyplexes containing plasmid coding for mammalian secreted
alkaline phosphatase (SEAP) were used to transfect HEK293 cells after lyophilization and transfection efficiency was
compared to freshly prepared polyplexes (Fresh). (C) The viscosity of the hydrogel precursor solution was increased through
addition of agarosein an attempt to prevent aggregation of polyplexes during gelation. Reprinted from [69] with permission
from Elsevier.
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natural polymers, NA incorporation may be achieved by
simple soaking of the hydrogel with NA, encapsulation of
vectors during hydrogel formation or physical or chemical
conjugation of NA or vector to the hydrogel matrix [71e74].
Furthermore, in situ forming hydrogels [75,76] and stimuli-
responsive systems [77,78] have been developed based on
synthetic polymers. Release properties may therefore be var-
ied according to the specific needs through the mode of NA
incorporation or by variation of scaffold properties. Takahashi
et al. varied the crosslinking density of PEG hydrogels to
modify the diffusion-controlled release of siRNA/PEI poly-
plexes [71]. NA release can be sustained even further through
conjugation of NA/vector complexes to the scaffold. Li et al.
used a triblock copolymers consisting of methoxy-PEG, poly(ε-
caprolactone) and poly[2-(dimethylamino)ethyl methacrylate
(MPEG-PCL-PDMAEMA) that efficiently condensed plasmid
DNA to generate hydrogels by crosslinking mPEG blocks using
a-cyclodextrin [74]. Using this supramolecular hydrogel, sus-
tained release of DNA for up to 6 days was achieved.
Efficient cell infiltration is another critical property for
hydrogel delivery system employed for tissue engineering
and therefore control over the macroporous structure is
crucial. Orsi et al. developed hydrogels with variable and
controllable pore size distribution based on PEG hydrogels
using gelatin microparticles for templating, achieving
improved and controllable cell migration into the scaffold
[79]. Similarly, matrix stiffness of hydrogels affects NAdelivery performance and was shown to be inversely related
to transfection efficiency in hydrogels [80,81]. Keeney et al.
synthesized hydrogels with a tunable matrix stiffness be-
tween 2 and 175 kPa using PEG-dimethacrylate (PEG-DMA)
and gelatin-methacrylate (Gelatin-MA) [82]. Cells were
coencapsulated with polyplexes inside hydrogels and cell
proliferation and transfection efficiency was investigated.
While cell proliferation decreased with matrix stiffness,
transfection efficiency of optimized polyplexes was found to
be high across a broad stiffness range, but being strongly
reduced at high gel stiffness (Fig. 2). Therefore it is important
to note that besides optimization of vector efficiency and
release rate, mechanical and physical properties of the ma-
trix such as porosity and stiffness may be important opti-
mization parameters, especially in case where cell
infiltration into the scaffold is intended.
3.2.1.3. Bioresponsive hydrogels. Despite the progress made
using hydrogel-based delivery, release of NA vectors for such
composite systems is controlled solely by hydrogel and vector
properties, such as diffusion- and degradation rate or vector/
hydrogel interactions. In contrast, bioresponsive drug delivery
systems have been developed in recent years. These systems
change their properties in response to a biological trigger such
as changes of the pH, temperature, light or presence of bio-
molecules such as enzymes [83]. Such functions are highly
desirable when designing hydrogels for NA delivery, allowing
novel modes of drug release, e.g. self-regulating systems that
Fig. 2 e Analysis of cell proliferation and transfection
efficiency using luciferase as reporter gene of HEK293 cells
8 days after coencapsulation with polyplexes into PEG-
DMA/Gelatin-MA hydrogels. Bars or points with shared
letters are not statistically different from each other.
Uppercase letters apply to luciferase expression. Reprinted
from [82], with permission from Elsevier.
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the numerous bioresponsive systems described to date,
hydrogels that release their payload in the presence of
elevated levels of enzymes will be discussed in more detail.
Cell-matrix interactions represent an interesting trigger for
drug release from hydrogels, especially for tissue engineering
applications. Matrix metalloproteinases (MMPs) are enzymes
that degrade both, matrix and non-matrix proteins, and are
important for remodeling of the extracellular environment of
cells [84]. MMP-degradable hydrogels support cell growth and
allow cell migration and have been intensively studied by
Hubbell and coworkers and others [85e87]. The significant
potential of MMP-degradable hydrogels as drug delivery ma-
trix was recently highlighted by Purcell et al., incorporating
recombinant tissue inhibitor of MMPs (rTIMP-3) into MMP-
sensitive hydrogels [88]. MMP activity in a porcine model of
myocardial infarction was significantly reduced after targeted
delivery of hydrogel/rTIMP-3 and left ventricular remodeling
was attenuated. However, both the loading capacity of
hydrogels as well as the stability of proteins within hydrogels
is limited, representing a significant hurdle to efficient, long-
term treatment in many fields. Therefore the targeted,
stimuli-responsive delivery of plasmid DNA or siRNA through
MMP-sensitive hydrogels may represent an attractive alter-
native, allowing long-term bioavailability since cells infil-
trating the scaffold act as bioreactors for the required
proteins. NA delivery from MMP-degradable hydrogel
matrices has been recently investigated by Tatiana Segura and
coworkers [78,80,89]. In these studies, it was shown that
hydrogels loaded with non-viral vectors and allowing cell
infiltration by MMP-sensitive crosslinking resulted in long-
lasting transgene expression in combination with low
cytotoxicity.3.2.2. Porous structures
In contrast to hydrogels, microporous structures as discussed
herein are solid, porous or foam-like matrices typically
composed of polymers like polyurethans or poly(lactic-co-
glycolic acid) (PLGA) and intended for implantation or topical
application as opposed to injection. Such scaffolds may be
prepared through a variety of methods, including top-down
approaches such as simple foam forming and electro-
spinning, or bottom-up approaches such as microparticle
composites. In the following paragraphs we will focus on
foam-like structures and electrospun scaffolds, representing
frequently applied technologies. One of the main challenges
associated with solid porous structures for localized NA de-
livery is to achieve both, optimal cell infiltration as well as
appropriate release of NA. To fulfill the requirement of
optimal cell infiltration, structures of sufficiently high porosity
are fabricated. On the other hand, such highly porous struc-
tures are frequently characterized by very thin walls sepa-
rating the pores, which results in short diffusion distance and
fast release if drugs are simply encapsulated into the scaffold.
However, despite these challenges, solid structures allow for
substantial variation of material composition, structure and
surface modification and because of this flexibility are highly
interesting for the development of multifunctional NA de-
livery systems.
3.2.2.1. Foam-like scaffolds. Biodegradable polyurethans
(PUR) are promising foam-like biomaterials with proven per-
formance as injectable drug delivery system for various small
chemical and biologic drugs [90e94]. PURs suitability for NA
delivery has recently been evaluated by Nelson et al. [95,96].
SiRNA was complexed into nanoparticles using a diblock
copolymer composed of 2-(diethylamino)ethyl methacrylate,
butyl methacrylate and 2-propyl acrylic acid and nano-
complexes were encapsulated into the matrix during PUR
foam preparation. These scaffolds were shown to release
nanocomplexes over 3 weeks based on a diffusion-controlled
mechanism and bioactivity of siRNAwasmaintained for 4e21
days depending on the model used [95,96]. The therapeutic
potential of PUR scaffolds was evaluated in vivo after subcu-
taneous implantation of scaffolds into balb/c mice. SiRNA
targeting prolyl hydroxylase domain protein 2 (PHD2) was
encapsulated into scaffolds as described above. During nor-
moxia PHD2 activity results in degradation of pro-angiogenic
hypoxia inducible factor 1a (HIF1a). Suppression of PHD2
therefore results in enhanced activity of HIF1a, mediating
expression of pro-angiogenic vascular endothelial growth
factor (VEGF), fibroblast growth factor 2 (FGF-2), and others
[96]. After 14 days, VEGF and FGF-2 expression increased
approximately 200% and 300%, respectively and a significantly
improved development of functional vascular structures was
imaged and quantified by micro-CT (Fig. 3), providing pre-
liminary evidence for therapeutic efficiency of such scaffolds
in vivo.
An alternative approach was followed by Rives et al.,
applying a sandwich approach where the structure of the
polymeric material was varied in an attempt to uncouple
scaffold structural requirements from requirements of drug
delivery [97]. The authors prepared layered poly(lactic-co-
Fig. 3 e Delivery of siRNA directed against PHD2 increases expression of VEGF and FGF-2 and improves neovascularization.
A) PHD2 was efficiently silenced through application of PHD2-siRNA loaded nanoparticles (PHD2-NP) whereas scrambled
siRNA (SCR-NP) had no significant effect versus non-treated (NT) cells. Silencing of PHD2 resulted in significantly increased
expression of VEGF and FGF-2. B) Micro-CT imaging revealed improved vessel formation after application of PHD2-NP
vasculature. C) Analysis of micro-CT images showed a significant increase of both vessel number and vessel size for PHD2-
NP scaffolds compared to application of scaffolds loaded with scrambled siRNA. Reprinted from [96] with permission from
Wiley.
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allowing cell infiltration, and non-porous layers containing
plasmidDNA and allowing slow release. The non-porous layer
was fabricated from PLGA microparticles and loaded with
plasmid DNA. It was then sandwiched between two porous
layers, which were fabricated from PLGAmicroparticles using
gas foaming in combination with particle leaching. These
scaffolds allowed efficient cell infiltration into the outer
porous layers. Pronounced burst release of plasmid DNA was
observed within the first 3 days, resulting in declining trans-
gene expression after 3 days. However, after implantation of
scaffolds loaded with plasmid DNA encoding FGF-2 into
intraperitoneal fat of C57BL/6 mice, a significant increase in
the total vascular volume fraction was achieved, in part being
a result of an increase in vessel size. Nevertheless, achieving
more sustained plasmid release kinetics would potentially
extend transgene expression and reduce plasmid-associated
inflammatory response [97].
Finally, additive manufacturing (also known as 3D printing
or rapid prototyping) is another approach followed to fabricate
scaffolds with just the right combination of properties. In
contrast to traditional scaffold manufacturing methods rapid
prototyping allows the fabrication of complex structures
composed of different materials and does not require the use
of toxic solvents. Andersen et al. recently presented scaffolds
composed of an NA-loaded hydrogel component and poly-
caprolactone for structural stability fabricated by additive
manufacturing [98]. The hydrogel composition was optimized
to achieve printability by hydroxyethylcellulose, stability by
alginate and cell attachment and survival by hyaluronan and
the gels were loaded with siRNA and used for 3D printing as
shown in Fig. 4.
In order to improve load-bearing ability of scaffolds,
hydrogels were co-printed with PCL fibers, resulting in scaf-
folds that were impossible to crush by hand. These composite
scaffolds could be seeded with stem cells and encapsulated
siRNA was shown to stay localized and being taken up by
nearby cells. Image analysis further revealed that localized
knockdown of green fluorescent protein (GFP) used as reportergene could be achieved in checker patterned scaffolds with
alternating patches with siRNA targeting GFP and mis-
matched siRNA (Fig. 5) [98].
3.2.2.2. Electrospun matrices. The structural similarity of
electrospun nonwovens to the extracellular matrix and their
wide variability with regards to composition and dimension of
individual fibers as well as structure of nonwovens have
resulted in significant attention on the electrospinning tech-
nique in the biomaterials and tissue engineering fields [99].
Numerous polymers, such as PLGA, PCL and PEG as well as
various fabrication techniques such as emulsion electro-
spinning, coaxial electrospinning or two-nozzle electro-
spinning may be used and combined [99]. Furthermore,
subsequent modification of the fiber surface opens additional
options for the fabrication of complex composite materials.
Herein we will highlight some recent developments in the
field of electrospun nonwovens for nucleic acid delivery,
focusing on novel techniques that go beyond diffusion-based
release of NA from electrospun polymer fibers representing
the first generation of electrospun NA delivery systems
[100e102]. Burst release of large amounts of loaded NA was a
major challenge associated with some of these early systems
[100,101]. However, this problem could at least partly be
solved through encapsulation of NA/polycation complexes
into nonwoven scaffolds [102,103]. Saraf et al. prepared core/
shell fibers using PCL, PEI and hyaluronic acid (HA) as shell
material, while PEG and DNA were located in the core of the
fibers [103]. The effects of variation of four processing pa-
rameters, on fiber diameter, release kinetics of PEI-HA and
transfection efficiency were evaluated based on a fractional
factorial design. The average transfection efficiency was
affected by PEG molecular weight and concentration and las-
ted for up to 60 days under optimized conditions in vitro. An
alternative approach to encapsulation of NA into polymer fi-
bers was presented by Sakai et al., who used a layer-by-layer
assembly to load NA onto the fiber surface [104]. In this
study, plasmid DNA and PEI were employed as polyanion and
polycation, respectively to achieve successive deposition and
Fig. 4 e Schematic representation of scaffold manufacturing procedure using additive manufacturing approach. Reprinted
from [98], with permission from Wiley.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 1 5 9e1 7 5166multilayer buildup. Transfection efficiency of scaffolds pre-
pared using this coating technique depended both on the
amount of DNA loaded onto the scaffolds as well as on incu-
bation time with cells.
Interestingly, several studies reported that significant
cytotoxicity of polyplexes was observed despite encapsulation
or adsorption of polyplexes to electrospun nonwovens, which
was at least in part attributed to significant burst release
[100e102]. In a recent study the cytotoxicity and transfection
efficiency of polyplexes encapsulated into the innermost or
the outermost layer of microcapsules consisting of silk fibroin
was directly compared in vitro [105]. From these experimentsit became evident that encapsulation of polyplexes signifi-
cantly reduced cytotoxicity while maintaining transfection
efficiency. Furthermore, both, cytotoxicity and transfection
efficiency were reduced when polyplexes were incorporated
into the innermost layer compared to polyplexes being pre-
sent in the outermost layer. One might therefore conclude
that despite a significant reduction of cytotoxicity of poly-
plexes can be achieved through encapsulation and sustained
release, delivery systems must still be optimized to achieve a
proper balance of transfection efficiency versus cytotoxicity.
Recent reports showed that electrospun scaffolds are quite
suitable for designing bioresponsive NA delivery systems
Fig. 5 e Checker patterned scaffolds consisting of PCL fibers and hydrogel containing siRNA directed against GFP or
mismatched siRNA. A) GFP expressing human mesenchymal stem cells were seeded into the scaffold and imaged at day 3
using a laser fluorescence scanner. B) The resulting image was cropped and centered on the scaffold. C) Bilinear
downsampling to 4 £ 4 pixels representing 4 £ 4 siRNA patches was performed. D) The fluorescence level of each pixel
represented by its color value was determined and is shown as mean and standard deviation of 8 samples for each group.
Reprinted from [98], with permission from Wiley.
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coupled via an MMP-sensitive linker onto the surface of elec-
trospun fibers consisting of PCL-PEG copolymer [106,108,109].
Upon incubation with plasmid DNA or siRNA, efficient
complexation of NAwith surface-bound PEI was observed and
MMP activity resulted in release of PEI/DNA complexes and
bioresponsive transfection (Fig. 6). The therapeutic efficiency
of this approach was evaluated in an in vivomodel of diabetic
ulcers, either using plasmid DNA encoding for human
epidermal growth factor (hEGF) [108] or employing siRNA
targeted at MMP-2 [109]. In both cases, accelerated wound
recovery was observed, either through increased expression
of hEGF leading to enhanced re-epithelialization or through
reduction of MMP-2 expression resulting in normalization of
the wound milieu. These studies show the potential of bio-
responsive delivery systems based on electrospun scaffolds
with regards to achieving and maintaining just the right drug
concentration in response to and controlled by a specific dis-
ease state. Further developments will likely focus on
improved protection of NA during storage and after applica-
tion, increased loading capacity for NA and simplified syn-
thesis and fabrication of these systems.
Finally, electrospun scaffolds allow the combination of
various delivery systems and drugs within one device as well
as significant structural variability. The ability to combine
different NA within one scaffold is exemplified by studiesconducted by Li and colleagues who coencapsulated plasmid
DNA coding for VEGF (pVEGF) and FGF (pFGF) into core/shell
fibers by emulsion electrospinning [110,111]. In a first study
the core contained plasmid DNA/PEI polyplexes while the
shell consisted of poly(DL-lactide)-poly(ethylene glycol) (PELA)
[111]. The release kinetics of plasmid DNA from fibers con-
taining only pVEGF was very similar to fibers containing both
plasmids and both types showed low burst release of
approximately 10% (Fig. 7A). Cytotoxicity of polyplexes
released from scaffolds was evident but was reduced when
polyplexes were encapsulated into the core of the fibers
compared to fiber mats where polyplexes were adsorbed to
the surface (Fig. 7B). The authors also observed that cell pro-
liferation after approximately 3 days was more pronounced
for scaffolds with encapsulated polyplexes than for adsorbed
polyplexes. This was attributed to sustained release of
plasmid, resulting in long-lasting transfection and increased
growth promotion through the expressed growth factors.
Despite the fact that these scaffolds successfully promoted
the generation of blood vessels in vivo, low cell viability, pro-
nounced inflammation and necrosis lead to the development
of a system using calcium phosphate/DNA (CP/DNA) nano-
particles instead of PEI/DNA polyplexes [110]. It was assumed
that the transfection efficiency of plain CP/DNA nanoparticles
decreases over time due to aggregation and growth of nano-
particles, finally resulting in particles too large for cellular
Fig. 7 e A) In vitro release of plasmid DNA from electrospun fibers containing pVEGF alone (Fv) or combined pVEGF and pFGF
(Fv-b). B) Cell attachment 4 h after seeding and cell viability at different time points after incubation of HUVEC with plasmid
DNA polyplexes encapsulated into fibrous mats Fv and Fv-b, or plasmid DNA polyplexes infiltrated into empty fibrous mats
with pVEGF alone (F0þv) or both pVEGF and pFGF (F0þv-b) compared to empty fibrous mats (F0) and tissue culture plastic
(TCP). Reprinted from [111], with permission from Elsevier.
Fig. 6 e Schematic presentation of MMP-sensitive immobilization of PEI on the surface of electrospun fibers. A) Synthesis of
PEI-grafted PCL-PEG fibers: an MMP-sensitive peptide linker was conjugated with free primary amines on the fiber surface
through 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide/N-hydroxysuccinimide (EDC/NHS) chemistry, followed by
conjugation of N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP)-activated PEI to free terminal cysteine of the peptide
linker. B) Schematic presentation of fabrication of the drug delivery system and bioresponsive release. Reprinted from [106],
with permission from Elsevier.
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DNA nanoparticles into electrospun fibers might alleviate this
phenomenon. CP/DNA nanoparticles indeed significantly
reduced cytotoxicity and inflammation reaction compared to
PEI/DNA polyplexes. Furthermore, the combined encapsula-
tion of pVEGF and pFGF was shown to be more effective with
regards to the density of newly formed blood vessels in vivo
than delivery of individual plasmids [110].
3.3. Physical methods
Besides polymer- and liposome-based non-viral systems,
several physical methods have been applied for the localized
administration of NA in an attempt to improve safety, efficacy
and targeting. Physical approaches to NA delivery include
hydrodynamic methods, iontophoresis, microneedles, ultra-
sound and electroporation. The latter two methods are most
frequently applied and are described in more detail in the
following sections.
3.3.1. Ultrasound
Ultrasound facilitated delivery (sonoporation) of nucleic acids
is probably the physical method, which is most often applied
for localized delivery. Sonoporation relies on the transient
formation of pores in the cell membrane in the presence of
microbubbles, resulting in efficient uptake of various mole-
cules into the cells [113]. Microbubbles have been used as ul-
trasound contrast agents for several decades and various
formulations are commercially available and FDA approved
for human use (e.g. SonoVue® from Bracco International,
Optison® from Mallinckrodt and Definity® from Lantheus
Medical Imaging). However, besides use as a contrast agent,
these microbubbles have also been recognized as drug de-
livery vehicles for non-permeable molecules such as macro-
molecular drugs and NA [114,115]. Deshpande and Prausnitz
showed in vitro that the combination of sonoporation using
Optison microbubbles and PEI/DNA complexes significantly
improved transfection efficiency over each of the treatments
alone [116]. Similarly, improved cytoplasmatic uptake of lip-
oplexes through cell membrane pores was observed [117].
Ultrasound facilitated delivery was also successfully used for
siRNA transfection with naked siRNA [118], siRNA-liposome
complexes [119] and siRNA-polycation complexes [120].
These studies point towards potential improvements of NA
delivery efficiency in vivo using ultrasound. Already in 2003,
Pislaru et al. found that ultrasound exposure enhanced gene
delivery efficiency in rat skeletal muscle after intramuscular
injection of microbubbles mixed with naked plasmid DNA
coding for luciferase compared to the same formulation
without ultrasound application [121]. A dose-related increase
of ultrasound facilitated transfection efficiency was observed
and transfections through sonoporation were spatially highly
restricted compared to control experiments with adenoviral
gene transfer (Fig. 8). Interestingly, significant differences in
transfection efficiency in different muscles were observed,
which were unexpected and attributed to flaws inherent to IM
injection and varying doses per volume in the different mus-
cles [121].
Another approach to utilizing sonoporation for the
spatially restricted transfection of tissues was presented byKowalczuk et al. [122]. In this study, transfection of the ocular
ciliary muscle with naked DNA in combination with micro-
bubbles and ultrasound was investigated. Similar to the study
by Pislaru et al., significantly improved gene expression was
observed after ultrasound treatment. Despite a rise of lens and
ciliary muscle temperature during the treatment, no damage
to the tissue was observed. Unfortunately, the study was
performed using reporter genes only (luciferase, green fluo-
rescent protein (GFP) and b-galactosidase) but nevertheless
shows that expression of therapeutic proteins in the ciliary
muscle is potentially feasible.
Ziadloo, Xie and Frenkel recently presented an alternative
approach to gene delivery through sonoporation [123]. In
contrast to many studies in the field, no microbubbles were
used to improve ultrasound efficiency. Instead, pulsed,
focused ultrasound (pFUS) was applied immediately prior to
intratumoral injection of naked tumor necrosis factor alpha
(TNF-a) plasmidDNA. Exposure to pFUS alone had no effect on
tumor growth compared to the control group. Injection of
TNF-a plasmid DNA alone (without pFUS treatment) resulted
in significant tumor growth inhibition, which was further
significantly improved after pFUS treatment in combination
with TNF-a plasmid. Histological evaluation of the tumors
revealed larger necrotic regions and improved distribution
and penetration of fluorescent surrogate nanoparticles after
pFUS treatment. The authors therefore conclude that besides
the structural effects of ultrasound treatment that resulted in
an increase of the pore size of the tissue and enhanced dis-
tribution of the plasmid, the enlarged space between cells
could have also improved the hydraulic conductivity. This
would result in increased fluid flow from the tumor core to its
periphery and further contribute to improved penetration and
distribution of the injected solution (Fig. 9).
3.3.2. Electroporation
The permeability of the cell membrane for non-permeable,
macromolecular drugs can also be increased through appli-
cation of an external electrical field. Electroporation has
several advantages compared to polymeric and liposomal
transfection vectors: a) high transfection efficiency in pri-
mary cells is achievable, b) fewer safety concerns are asso-
ciatedwith thismethod, c) electroporation is easy to perform,
and d) efficiency is only marginally influenced by the cell line
used [124]. Over 30 years of research on electroporation [125]
have led to technologically quite advanced methods with
several systems being commercially available. Electropora-
tion has been tested in numerous clinical trials, providing
evidence that the method can be successfully applied in
clinical therapy [126]. Due to the wealth of reports available
and decades of research, we herein focus on selected recent
studies and otherwise refer to the reviews by Gotthelf and
Gehl [127] and Wells [128] for detailed information on
electroporation.
The basic mechanism of siRNA electroporation was
recently investigated on single-cell level by Paganin-Gioanni
et al. [129]. In this study, electrotransfer of NA was directly
observed by confocal microscopy, providing evidence for the
direct transfer of siRNA across the cell membrane. Electro-
permeabilization occurred on the two opposite sides of the
cell facing the electrodes, whereas siRNA entry was found to
Fig. 8 e A and B: Reporter gene expression 3 days after i.m. injection of luciferase plasmid into the triceps brachii. A: Effect of
ultrasound (US) treatment on transfection efficiency of different vectors. From left to right: plasmid þ perfluorocarbon
exposed sonicated dextrose albumin (PESDA) þ diagnostic US; plasmid þ PESDA þ continuous wave US;
plasmidþ diagnostic US; plasmidþ PESDA, no US; plasmid alone, no US; plasmidþ LipofectAmine®, no US; adenovirus, no
US. B: Dose-response of plasmid sonoporation in the presence of PESDA (filled bars) vs. plasmid alone without US (open
bars). C: Transfection efficiency in gastrocnemius (open bars) and in the triceps brachii (filled bars) at different dose levels. D:
Luciferase expression in the liver after treatment with different doses of plasmidþ PESDAþ US (filled bars) and adenovirus
(striped bar). *P < 0.05 vs. corresponding open bar; yP < 0.05 vs all filled bars. Reproduced with permission of Oxford
University press from [121].
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electrophoresis aids in electrotransfer. Interestingly, the
mechanism of siRNA electrotransfer was found to be some-
what different from plasmid DNA transfer. While siRNA
appeared to rapidly and freely penetrate the cell membrane
during electroporation, plasmid DNA first formed long-lived
spots on the plasma membrane and translocation into the
cytoplasm occurred in a second step several minutes after
electroporation took place.
Electroporation is well established for the transfer of DNA
and extensive studies provided both optimized electropora-
tion devices as well as e parameters. However, fewer studies
have investigatedmethods for optimal RNA delivery. Knowing
that the basic mechanisms of electroporation-enhanced NA
transfer on a cellular level differ between DNA and RNA, it
might be hypothesized that optimal transdermal transfer
conditions might be widely disparate. Broderick et al. studied
in vivo transdermal electroporation for both DNA and siRNA
[130]. It was shown in this study that a) low voltage electro-
poration (10 V range) elicited the most robust transfection for
plasmid DNA and b) the same parameters applied for plasmid
DNA resulted in successful electrotransfer of siRNA. Overall,
no site inflammation or tissue damage was observed usingthis procedure confirming the good tolerability of low voltage
electroporation.
From a patient perspective, topical electroporation-
enhanced NA delivery might appear inconvenient due to the
necessity of intradermal injection followed by more or less
invasive electroporation. Lee et al. therefore developed a
monolithic hybrid system consisting of a dissolving micro-
needle and an electrode to combine both stepswithin the same
device (Fig. 10) [131]. In contrast to NA-coated metal micro-
needles, this system allows the transfer of significantly larger
amounts of NA into the skin, leading to improved therapeutic
efficiency. The dissolving microneedles were produced
through antidromic isolation by drawing lithography from
maltose using the aluminum electrode as drawing pillar and
were loaded with plasmid DNA coding for luciferase. Insertion
of this device into the skin bypasses the stratum corneum and
releases DNA into the interstitial space of the skin. Electropo-
ration can be performed directly through the electrode. Using
these hybrid microneedles, subcutaneous tumors were treated
with plasmid DNA containing the proinflammatory cytokine
interleukin 12 in a mouse model. Hybrid electro-microneedles
were most efficient at suppressing tumor growth and with
regards to survival after tumor inoculation.
Fig. 10 e Schematic representation of (A) hybrid electro-microneedles consisting of an electrode pillar made from aluminum
and a dissolvable microneedle made from maltose. (B) Hybrid electro-microneedles are inserted into the skin, allowing
permeation of the stratum corneum and releasing DNA into the interstitium. Electroporation is directly performed using the
aluminum electrode. Reprinted from [131] with permission from Elsevier.
Fig. 9 e Schematic representation of the effect of pFUS on transfection with TNF-a plasmids. Top: Mechanical changes such
as enlarged space between parenchymal cells are induced by pFUS treatment. Middle: These mechanical effects improve
penetration and distribution of injected plasmid solution. Bottom: Therefore, a larger region of necrosis is observed,
ultimately leading to reduced tumor growth. Reprinted with permission from [123], Acoustic Society of America.
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Numerous approaches to local delivery of NA have been
published in recent years. Besides drug delivery systemsintended for topical or localized therapy, tissue engineering
has been a main driver for research and development.
Without reiterating the basic considerations as described in
the introduction, it should be emphasized here that for ap-
plications where the drug delivery system is in direct contact
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a promising alternative to protein or peptide delivery due to
higher stability of NA and the ability to employ resident cells
as bioreactors. Significant progress has been made in the past
decades in the development of non-viral vectors for gene de-
livery, which forms the basis for scaffold-based NA delivery.
However, systemic administration of non-viral vectors is still
associated with problems such as insufficient blood half-life,
inefficient targeting and cytotoxicity, all of which can be
avoided or alleviated by localized delivery.
The discontinuation of the clinical development of naked
siRNA for treatment of choroidal and retinal neo-
vascularization was a setback for localized NA delivery in the
eye and the discovery of non-specific, TLR3-mediated effects
of siRNA has questioned the therapeutic suitability of naked
siRNA. Nevertheless, both the indication as well as the de-
livery route are still highly interesting. To improve siRNA
specific effects, further research into drug delivery systems
allowing protecting siRNA from degradation and unspecific
recognition and with the ability to facilitate efficient cellular
uptake is necessary.
The development of bioresponsive, enzyme sensitive de-
livery systems might result in a major improvement of drug
therapy as these systems add a new dimension to controlled
drug release. Current systems mainly focus on improved cell
migration within hydrogels facilitated by MMP-sensitive
crosslinks. However, some studies showed that MMP-
sensitive peptides may also be used to control drug release,
e.g. resulting in release of MMP inhibitors specifically at
elevated MMP levels. Advanced electrospun drug delivery
system might in the future use this concept for the self-
regulated control and normalization of the wound milieu,
while at the same time providing mechanical support and
protection from contamination by bacteria.
Finally, physical methods for NA delivery such as electro-
poration have been continuously developed for decades and
are highly versatile with regards to the type of NA used. The
combination of advanced electroporation techniques with
specializedmicroneedle arrays represents a clinically feasible,
relatively simple and potentially safe approach to dermal
delivery of NA. While the range of applications of such sys-
tems is limited compared to hydrogels or electrospun non-
wovens, their simplicity, the improved control over device
structure and the well-defined location of NA delivery might
represent significant advantages with regards to clinical
evaluation and regulatory acceptance.
Localized NA delivery therefore is a promising strategy for
the safe and efficacious treatment of numerous diseases.
Further development of non-viral vectors, nano- and micro-
structured scaffolds andNAderivatives is expected to result in
significant improvements with regards to controlled NA
release, biocompatibility of scaffolds and transfection
efficiency.r e f e r e n c e s
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